Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 4;37(3):656-672.e7.
doi: 10.1016/j.cmet.2024.11.001. Epub 2024 Dec 13.

FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology

Affiliations

FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology

Lexiang Yu et al. Cell Metab. .

Abstract

Immunoglobulin G (IgG) is traditionally recognized as a plasma protein that neutralizes antigens for immune defense. However, our research demonstrates that IgG predominantly accumulates in adipose tissue during obesity development, triggering insulin resistance and macrophage infiltration. This accumulation is governed by neonatal Fc receptor (FcRn)-dependent recycling, orchestrated in adipose progenitor cells and macrophages during the early and late stages of diet-induced obesity (DIO), respectively. Targeting FcRn abolished IgG accumulation and rectified insulin resistance and metabolic degeneration in DIO. By integrating artificial intelligence (AI) modeling with in vivo and in vitro experimental models, we unexpectedly uncovered an interaction between IgG's Fc-CH3 domain and the insulin receptor's ectodomain. This interaction hinders insulin binding, consequently obstructing insulin signaling and adipocyte functions. These findings unveil adipose IgG accumulation as a driving force in obesity pathophysiology, providing a novel therapeutic strategy to tackle metabolic dysfunctions.

Keywords: FcRn; IgG; adipose tissue remodeling; insulin receptor; insulin resistance; obesity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Kahn BB, and Flier JS (2000). Obesity and insulin resistance. J Clin Invest 106, 473–481. 10.1172/JCI10842. - DOI - PMC - PubMed
    1. Jin X, Qiu T, Li L, Yu R, Chen X, Li C, Proud CG, and Jiang T (2023). Pathophysiology of obesity and its associated diseases. Acta Pharmaceutica Sinica B 13, 2403–2424. 10.1016/j.apsb.2023.01.012. - DOI - PMC - PubMed
    1. Haeusler RA, McGraw TE, and Accili D (2018). Biochemical and cellular properties of insulin receptor signalling. Nat Rev Mol Cell Biol 19, 31–44. 10.1038/nrm.2017.89. - DOI - PMC - PubMed
    1. Qatanani M, and Lazar MA (2007). Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21, 1443–1455. 10.1101/gad.1550907. - DOI - PubMed
    1. Taylor SI (1992). Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41, 1473–1490. 10.2337/diab.41.11.1473. - DOI - PubMed

LinkOut - more resources